Target Price | $60.00 |
Price | $42.49 |
Potential |
41.21%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a John Wiley & Sons price target 2026.
The average John Wiley & Sons target price is $60.00.
This is
41.21%
register free of charge
|
|
A rating was issued by 1 analysts: 1 Analysts recommend John Wiley & Sons to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the John Wiley & Sons stock has an average upside potential 2026 of
41.21%
register free of charge
|
Apr '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 1.87 | 1.67 |
7.27% | 10.84% | |
EBITDA Margin | 21.64% | 24.05% |
3.36% | 11.16% | |
Net Margin | -10.49% | 4.39% |
1,369.77% | 141.83% |
1 Analyst has issued a sales forecast John Wiley & Sons 2025 . The average John Wiley & Sons sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast John Wiley & Sons 2025 . The average John Wiley & Sons EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast John Wiley & Sons 2025 . The average John Wiley & Sons net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Apr '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.65 | 1.36 |
1,277.42% | 137.26% | |
P/E | 31.24 | |
EV/Sales | 1.90 |
1 Analysts have issued a John Wiley & Sons forecast for earnings per share. The average John Wiley & Sons EPS is
This results in the following potential growth metrics and future valuations:
John Wiley & Sons...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.